Filing Flows › Lyell Immunopharma (LYEL) › Q4 2025
Lyell Immunopharma (LYEL) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 12, 2026
Lyell Immunopharma (LYEL) reported revenue of $6K for the fourth quarter 2025 (Q4 2025), -45% from a year earlier and -60% from the quarter before.
Lyell Immunopharma, Q4 2025: revenue $6K (-46% year over year), net loss $141M, operating cash flow −$32.3M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $6K | -60% | -45% |
| Operating profit | −$128M | — | — |
| Net earnings | −$141M | — | — |
| Operating cash flow | −$32.3M | — | — |
What changed
Revenue was $6K in Q4 2025, down 45% year over year and down 60% from the previous quarter.
Operating costs exceeded revenue by $127.6M, an operating margin of -2127400.0%. Total costs fell 37% while revenue fell 45%. The quarter ended with a net loss of $140.7M, wider than the previous quarter's $38.8M loss.
Operating cash flow was −$32.3M. Non-cash charges added back $2.4M of depreciation and amortization and $25.6M of share-based compensation. Working capital and other items added $80.5M. Capital expenditures of $304K exceeded it, leaving free cash flow of −$32.6M.
Questions
What was Lyell Immunopharma's revenue in the fourth quarter 2025?
Lyell Immunopharma (LYEL) reported revenue of $6K for the fourth quarter 2025 (Q4 2025), -45% from a year earlier and -60% from the quarter before.
Source: Lyell Immunopharma 10-K on SEC EDGAR.